Stock Research for ALPMY

ALPMY

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ALPMY Stock Chart & Research Data

The ALPMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ALPMY Due diligence Resources & Stock Charts

The ALPMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALPMY Detailed Price Forecast - CNN Money CNN View ALPMY Detailed Summary - Google Finance
Yahoo View ALPMY Detailed Summary - Yahoo! Finance Zacks View ALPMY Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ALPMY Trends & Analysis - Trade-Ideas Barrons View ALPMY Major Holders - Barrons
NASDAQ View ALPMY Call Transcripts - NASDAQ Seeking View ALPMY Breaking News & Analysis - Seeking Alpha
Spotlight View ALPMY Annual Report - CompanySpotlight.com OTC Report View ALPMY OTC Short Report - OTCShortReport.com
TradeKing View ALPMY Fundamentals - TradeKing Charts View ALPMY SEC Filings - Bar Chart
WSJ View Historical Prices for ALPMY - The WSJ Morningstar View Performance/Total Return for ALPMY - Morningstar
MarketWatch View the Analyst Estimates for ALPMY - MarketWatch CNBC View the Earnings History for ALPMY - CNBC
StockMarketWatch View the ALPMY Earnings - StockMarketWatch MacroAxis View ALPMY Buy or Sell Recommendations - MacroAxis
Bullish View the ALPMY Bullish Patterns - American Bulls Short Pains View ALPMY Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ALPMY Stock Mentions - StockTwits PennyStocks View ALPMY Stock Mentions - PennyStockTweets
Twitter View ALPMY Stock Mentions - Twitter Invest Hub View ALPMY Investment Forum News - Investor Hub
Yahoo View ALPMY Stock Mentions - Yahoo! Message Board Seeking Alpha View ALPMY Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ALPMY - SECform4.com Insider Cow View Insider Transactions for ALPMY - Insider Cow
CNBC View ALPMY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALPMY - OTC Markets
Yahoo View Insider Transactions for ALPMY - Yahoo! Finance NASDAQ View Institutional Holdings for ALPMY - NASDAQ


Stock Charts

FinViz View ALPMY Stock Insight & Charts - FinViz.com StockCharts View ALPMY Investment Charts - StockCharts.com
BarChart View ALPMY Stock Overview & Charts - BarChart Trading View View ALPMY User Generated Charts - Trading View




Latest Financial News for ALPMY


Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
Posted on Monday December 10, 2018

TOKYO , Dec. 10, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced that XOSPATA ® (generic name: gilteritinib) is now ...


Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Posted on Monday December 03, 2018

TOKYO , Dec. 3, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced updated results from a Phase 1 study of gilteritinib ...


XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
Posted on Wednesday November 28, 2018

- FLT3 mutation-positive AML is a life-threatening disease with significant unmet medical needs - - XOSPATA is the first and only FLT3 inhibitor approved by the FDA for patients with relapsed or refractory ...


Astellas Pharma gets U.S. nod for blood cancer treatment
Posted on Wednesday November 28, 2018

The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation. The treatment, Xospata, was approved for patients with acute myeloid leukemia (AML) with a FLT3 mutation, whose cancer has relapsed or proved treatment-resistant. The drug, taken once a day in tablet form, will have a wholesale acquisition cost of $22,500 for a month's supply, Astellas said.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.